What is SYNAPS Dx?
Based in Rockville, MD, SYNAPS Dx is dedicated to advancing the understanding and treatment of neurodegenerative diseases. The company's focus on this complex area of medical research positions it at the forefront of developing innovative solutions for conditions that affect millions globally. Its commitment to R&D in this specialized field highlights a strategic investment in future healthcare advancements.
How much funding has SYNAPS Dx raised?
SYNAPS Dx has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2021): $10M, investors not publicly disclosed
What's next for SYNAPS Dx?
With substantial enterprise-level capital infusion, SYNAPS Dx is poised for accelerated growth and expanded research initiatives. The company is expected to leverage this investment to further its development pipeline, potentially scaling its operations and deepening its impact in the neurodegenerative disorder space. This strategic financing will likely enable significant progress in clinical trials and the translation of research findings into tangible therapeutic outcomes.
See full SYNAPS Dx company page
